AnteAGE Exosomes and PEARL Multiplier With Microneedling for Facial Skin Quality

NCT07849205 | Completed

• 1 other identifier: 0003
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This exploratory clinical study evaluated changes in facial skin quality following a series of mechanical microneedling treatments combined with topical AnteAGE Exosomes and PEARL Multiplier and a standardized AnteAGE homecare regimen. Participants underwent three microneedling treatments at approximately 4-week intervals. Outcomes included instrumental skin measurements, standardized facial imaging, investigator assessments, participant-reported outcomes, and assessment of treatment tolerability.

Conditions

Skin Aging; Skin Quality

Keywords

Skin Aging; Skin Quality; Exosomes; PDRN; Microneedling

Outcome Measures

Primary Outcomes (3)

• Change from baseline in Skin Elasticity

  Skin elasticity was assessed instrumentally as average skin retraction time. Change from baseline in skin retraction time was evaluated over the 12-week study period, with decreased retraction time indicating faster skin recovery and improved elasticity.

  Baseline, Week 4, Week 8, and Week 12

• Change From Baseline in Coarse Facial Wrinkle Total Area

  Facial wrinkles were assessed using standardized VISIA facial imaging. Coarse wrinkle total area was quantified at each assessment, and change from baseline was evaluated over the 12-week study period. Decreased coarse wrinkle total area indicates improvement in facial wrinkle appearance.

  Baseline, Week 4, Week 8, and Week 12

• Change From Baseline in Transepidermal Water Loss (TEWL)

  Skin barrier function was assessed by measurement of transepidermal water loss (TEWL), expressed in g/m²/h. Change from baseline in TEWL was evaluated over the 12-week study period, with lower TEWL indicating reduced transepidermal water loss and improved skin barrier function.

  Baseline, Week 4, Week 8, and Week 12

Secondary Outcomes (3)

• Change From Baseline in Facial Red Features

  Baseline, Week 4, Week 8, and Week 12

• Participant-Reported Improvement in Skin Quality

  Week 12

• Incidence of Treatment-Emergent Adverse Events

  From first treatment through Week 12

Study Arms (1)

Microneedling With AnteAGE Exosomes and PEARL Multiplier

EXPERIMENTAL

Participants underwent three mechanical microneedling treatments approximately 4 weeks apart. AnteAGE Exosomes and PEARL Multiplier were applied topically during and/or immediately following microneedling. Participants followed a standardized homecare regimen consisting of AnteAGE Serum, Accelerator and Cleanser used daily, AnteAGE Face Mask used weekly, and daily SPF 30+.

Procedure: Mechanical microneedling; Other: AnteAGE Exosomes and PEARL Multiplier; Other: AnteAGE Homecare Regimen

Interventions

Mechanical microneedling PROCEDURE

Mechanical facial microneedling was performed using the Candela Exceed device on three occasions approximately 4 weeks apart.

Microneedling With AnteAGE Exosomes and PEARL Multiplier

AnteAGE Homecare Regimen OTHER

Participants used AnteAGE MD Serum, Accelerator and Cleanser daily, AnteAGE Face Mask weekly, and SPF 30+ daily during the study.

Microneedling With AnteAGE Exosomes and PEARL Multiplier

AnteAGE Exosomes and PEARL Multiplier OTHER

Topical AnteAGE Exosomes and PEARL Multiplier were applied during and/or immediately following mechanical microneedling according to the study protocol.

Microneedling With AnteAGE Exosomes and PEARL Multiplier

Eligibility Criteria

• Age: 35 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female participants aged 35-65 years
• Fitzpatrick Skin Types I-VI
• In good general health and able to comply with study procedures
• Willing to abstain from non-study topical treatments and cosmetic procedures during the study
• Able to provide written informed consent

You may not qualify if:

• Active skin infection or inflammatory skin condition
• Systemic retinoid use within 6 months
• Corticosteroid or immunomodulator use within 4 weeks
• History of keloid formation or hypertrophic scarring
• Facial cosmetic procedures within 3 months
• Pregnant or breastfeeding
• Uncontrolled medical condition or bleeding disorder
• Known allergy to any study-product ingredient
• Use of photosensitizing medication

Sponsors & Collaborators

• Cellese Inc.: lead

Study Sites (1)

Cellese Inc.

Irvine, California, 92614, United States

Location

Study Officials

• Rob Knight, PhD

  Cellese Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 24, 2026
• First Posted: September 30, 2026
• Study Start: August 2, 2025
• Primary Completion: November 1, 2025
• Study Completion: November 1, 2025
• Last Updated: September 30, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)